Last €4.97 EUR
Change Today 0.00 / 0.00%
Volume 201.0
ALNOV On Other Exchanges
EN Paris
As of 9:30 AM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).

novacyt (ALNOV) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/31/13 - €8.00
52 Week Low
07/14/14 - €4.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NOVACYT (ALNOV)

Related News

No related news articles were found.

novacyt (ALNOV) Related Businessweek News

No Related Businessweek News Found

novacyt (ALNOV) Details

Novacyt Société Anonyme develops and markets liquid-based cytology solutions for applications in the molecular biology field. The company offers NovaPrep processor system for mass screening and personalized diagnosis of cancerous and precancerous lesions. It also provides consumables, which include Gyn vial that holds smear samples and enhances the number of cells collected from the smear; Non-Gyn vial, which collects samples and optimizes the quantity of cells collected; Novastic, a liquid solution that optimizes the adherence of cells onto the glass slide; and sedimentation systems. The company offers its products through a network of distributors in France and internationally. Novacyt Société Anonyme was founded in 2006 and is based in Vélizy-Villacoublay, France.

9 Employees
Last Reported Date: 04/29/14
Founded in 2006

novacyt (ALNOV) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

novacyt (ALNOV) Key Developments

Novacyt Société Anonyme Announces Sales Results for the Six Months Ended June 30, 2014

Novacyt Société Anonyme announced sales results for the six months ended June 30, 2014. For the period, the company reported 42% increase in Group sales to EUR 827,200 compared with EUR 581,900 for the same period last year.

Novacyt Société Anonyme Reports Earnings Results for the Year 2013

Novacyt Société Anonyme reported earnings results for the year 2013. For the year, the company saw its net loss expand to EUR 993,000 (USD 1.4 million) from EUR 556,000 in 2012, according to audited results. The reason behind the bigger loss is a surge in operating costs to EUR 2.5 million from EUR 1.7 million, reflecting higher personnel and research and development costs. Revenues jumped 9% to EUR 1.2 million, of which domestic sales represented EUR 494,000, up 12%.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNOV:FP €4.97 EUR 0.00

ALNOV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALNOV.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALNOV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.6x
Price/Book 6.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVACYT, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at